Figure S4 from Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner

S4. (a) Representative immunostaining of Pt-(GpG) adducts in KP and KPE cell lines after cisplatin exposure (left). Quantification of Pt-(GpG) adduct staining in KP (n = 5) and KPE (n = 6) cells after cisplatin exposure (right). P values were calculated using two-tailed t-test. (b) Clonogenic survival assay of mock-treated KP and cisplatin-treated KP cells, mock-treated KPE and cisplatin-treated KPE cells, mock-treated KPE post cis and cisplatin-treated KPE post cis cells, mock-treated KPE post cis clone 6 (*6) and cisplatin-treated KPE post cis clone 6 (*6). (c) Detailed representation of Fig. 4c.